Vancomycin (VCM) is a glycopeptide antibiotic that is generally used to treat methicillin-resistant Staphylococcus aureus (MRSA). Recently, it has been reported that VCM clearance (CL) is signiˆcantly higher in elderly patients and infants and children with malignancies, compared with those without malignancies. We have treated many patients with a variety of malignant tumors in whom serum VCM concentrations were found to be moderately lower during therapeutic drug monitoring (TDM). The aim of this study was to determine whether the presence of malignant tumors in‰uences trough concentrations of VCM and VCM pharmacokinetics in elderly patients during treatment for MRSA infection. Comparison of the clinical characteristics and VCM pharmacokinetic parameters between patients with and without malignancies was undertaken in 49 elderly Japanese patients infected with MRSA. The mean trough concentration of VCM in patients with malignancies was signiˆcantly lower than that in patients without malignancies. Our results showed signiˆcantly higher values of VCM CL and volume of distribution and a shorter elimination half-life in patients with malignancies. Univariate logistic regression analysis of the pharmacokinetic parameters indicated that VCM CL contributed as a signiˆcant factor independent of the relation to malignant tumor. In conclusion, it is suggested that the therapeutic eŠects and side eŠects of VCM should be actively monitored using TDM, because concentrations may decrease when CL increases in VCM therapy for elderly patients with malignant tumors.
INTRODUCTION
Vancomycin (VCM) is a glycopeptide antibiotic that is generally used for the treatment of gram-positive infections, particularly methicillin-resistant Staphylococcus aureus (MRSA). 1 4) VCM is mainly eliminated from the body via the kidney. 5) Therefore altered renal function is very important in modifying VCM pharmacokinetics. 6) Therapeutic drug monitoring (TDM) is necessary to increase the e‹cacy of VCM in the treatment of MRSA infection. We generally plan VCM administration using the trough concentration as one measure. We have treated many patients with a variety of malignant tumors in whom the serum VCM concentrations were found to be moderately lower based on TDM data obtained in our hospital, despite the fact that this drug was administered in accordance with the package insert instructions or the dose was increased.
The presence of malignancy in infants and children increases VCM clearance (CL), resulting in larger dosage requirements. 7, 8) Similarly, the presence of hematologic malignancies in adults also increases CL rate and shortens the half-life (t 1/2 ) of the drug, compared with those in adults without malignancies. 9) Although similar reports have been published, 10, 11) the mechanism of the pharmacophysiologic changes in VCM pharmacokinetics remains unclear. However, to date there have been no reports focusing on elderly patients with MRSA infection. The aim of this study was to determine whether the presence of malignant tumors in‰uences trough concentrations of VCM and VCM pharmacokinetics in elderly patients during treatment for MRSA infection.
MATERIALS AND METHODS

Patients
We studied 49 elderly Japanese patients infected with MRSA (37 men and 12 women) who received intravenous infusion of VCM (Shionogi & Co., Ltd., Osaka, Japan) from January 2003 to September 2007. Their age ranged from 65 to 92 years (n＝1), and malignant lymphoma (n＝1). The remaining patients (n＝28) had no malignancy. For each patient, the clinicopathologic parameters included gender; age; weight, serum creatinine (Scr); creatinine clearance (CrCL); trough concentration; daily VCM dosage; combination with furosemide; the presence or absence of edema, ascites, and pleural ‰uid; CL, volume of distribution (Vd); and elimination t 1/2 . Individual pharmacokinetic parameters were calculated using the Bayesian estimation method, 12) and a two-compartment model was adopted using population pharmacokinetic parameters for Japanese adult patients. 13) CrCL was subsequently estimated using the Cockcroft-Gault equation, 14 16) which considered Scr, weight, age, and gender.
Administration and Measurement of VCM
MRSA infection was treated with VCM at dosages of 1000 mg twice a day or once a day. Serum samples were collected after the steady state for VCM had been achieved (i.e., at least 72 h after the initiation of therapy). Samples for trough concentration were taken immediately prior to administration of the next scheduled dose. The serum concentration of VCM was measured using the ‰uorescence polarization immunoassay method (BML Inc., Tokyo, Japan).
Statistical Analysis
All data are expressed as mean±S.D. The clinical characteristics and VCM pharmacokinetic values were compared between patients with and without malignancies using the Mann-Whitney U-test and univariate logistic regression analysis. As the target functions for logistic regression analysis, CL, t 1/2 , and distribution volume were analyzed. The diŠerences in gender, combination with furosemide, and the presence or absence of edema, ascites, and pleural ‰uid were assessed using the chi-square test. The SPSS 11.5 software package (SPSS Inc., Tokyo, Japan) was used for all statistical analyses. A p-value of less than 0.05 was considered statistically signiˆcant.
RESULTS
Comparison of Clinical Characteristics between Patients with and without Malignancies
The clinical characteristics of the elderly patients examined in this study are shown in Table 1 . The Mann-Whitney U-test revealed that the mean trough concentration of VCM in patients with malignancies was signiˆcantly lower than that in patients without malignancies ( p＝ 0.0012). However, there were no signiˆcant diŠer-ences in gender, age, weight, Scr, CrCL, VCM daily dosage, or combination with furosemide between patients with and without malignancies.
Comparison of VCM Pharmacokinetic Parameters between Patients with and without Malignancies
The mean CL and Vd in patients with malignancies were increased signiˆcantly compared with those in patients without malignancies (Mann-Whitney Utest, p＝0.0213 and p＝0.0374, respectively). On the other hand, the mean t 1/2 in patients with malignancies was signiˆcantly lower than that in patients without malignancies ( p＝0.0423) ( Table 2) .
Independent Pharmacokinetic Parameters Related to Malignancies
Univariate logistic regression analysis of three pharmacokinetic variables VCM clearance, Vd, and t 1/2 indicated that VCM clearance contributed as a signiˆcant factor independent of the relation to malignant tumor ( p＝0.02; odds ratio, 14.97; 95％ conˆdence interval, 1.541 145.404) (Fig.  1) .
DISCUSSION
The use of the trough concentration of VCM and data from TDM improves e‹cacy and safety outcomes. In particular, the trough concentration of VCM is usually recommended to be less than 10 mg/ ml. 17) However, treatment with a dose of less than 10 mg/ml for MRSA infection sometimes leads to failure in many cases, so that a higher treatment concentration is necessary to ensure eŠectiveness, 18) i.e., in patients with malignant tumors 7 11) and endocarditis. 19) In the present study, our results support higher dosage requirements for MRSA infection in elderly patients with malignancies because of the lower trough concentrations of VCM. The data on the transition of VCM into peritoneal and pleural eŠusions is similar to that in blood (company data from Shionogi & Co., Ltd., Osaka, Japan). In addition, it is known that the Vd of VCM increases and the serum concentration decreases in edema and in peritoneal and pleural eŠusion in patients with malignant tumors. Therefore edema and peritoneal and pleural eŠusion were considered to increase the Vd and decrease the serum concentration. Therefore, we also further investigated patients with edema and peritoneal and pleural eŠusion, although, no signiˆcant diŠerences were observed. These results indicate that edema or peritoneal or pleural eŠusion may have little impact on the alteration of CL in patients with malignant tumors who undergo VCM therapy. Further investigation, including basic experiments regarding the transition of the drug into each organ, will be essential to investigate the cause.
Furthermore, our results also indicated higher CL rates in elderly patients with malignancies, supporting the previous reports and justifying the need for higher concentrations for elderly patients with malignancies. 7 11) Since VCM is mainly metabolized and excreted in the kidney, various degrees of renal function can in‰uence VCM pharmacokinetics. 6) In particular, the elderly generally exhibit renal hypofunction, and chemotherapy with anticancer drugs for malignancies induces various degrees of renal injury. However, there were no signiˆcant diŠerences in Scr and CrCL between patients with and without malignancies in this study; although CrCL obtained based on the Cockcroft-Gault formula would be overestimated when calculated based on Scr in elderly patients. 20) In this study, although no signiˆcant diŠerences were found in Scr and CrCL, the SD was large and the number of patients was insu‹cient. Since the possibility of second-class error was suspected, the examination was conducted with the level of statistical signiˆcance set at 10％ as well as 5％ and demonstrated no signiˆcant diŠerence, even at p＜ 0.1. Thus aging and the presence of malignancies may elevate CL independently, but not necessarily through changes in renal function. Since the CL of VCM is in‰uenced by renal function, actual measurement values from pooled urine should be used to evaluate renal function precisely. However, the population parameters of Yasuhara et al. 13) implemented in this study were estimated using the Cockcroft-Gault equation. Furthermore, the predictability of the serum concentration of VCM based on TDM estimated by the Cockcroft-Gault equation has been reported to be high in the elderly. 21) Thus, in this study, CrCL calculated with the Cockcroft-Gault equation was used as a substitute for the level of renal function.
Although the population parameters of Yasuhara et al. 13) target patients with MRSA infection, it is not clear whether the parameters include patients with malignant tumors. The population parameters of Yasuhara et al. 13) are cited in many reports of the TDM of VCM in Japan and the credibility is believed to be high, i.e., the parameters are considered adequate to determine diŠerences between patients with malignancies and those without. Thus the need to establish population parameters for patients with malignant tumors based upon a larger number of cases was suggested.
When Vd decreases or CL increases, the t 1/2 is shortened. In this study, we observed signiˆcantly higher values of CL and Vd and shorter t 1/2 in patients with malignancies. It has been reported that the terminal elimination half-life of VCM is prolonged and CL is lower in the elderly, aged 60 to 95 years, compared with those in the younger age group of 18 to 59 years, because of the altered disposition of VCM in the elderly. 22) Meanwhile, there were no signiˆcant diŠerences in VCM pharmacokinetic parameters between the elderly over 70 years of age (mean±S.D., 75.0±5.4 years) and the young. 23) Several pathophysiologic factors related to malignancy, such as cancer type, high-dose antineoplastic therapy, advanced disease stage, hypoalbuminemia, ‰uid overload, and cachexia may aŠect aminoglycoside pharmacokinetics. 24 28) We consider that factors related to malignant tumors changed the VCM pharmacokinetic parameters. However, since the current study sample size was relatively small, it remains to be conˆrmed whether thisˆnding is reproducible in larger samples.
In conclusion, it is suggested that the therapeutic eŠects and side eŠects of VCM should be actively monitored using TDM, because VCM concentrations may decrease when CL increases during the treatment of elderly patients with malignant tumors.
